The Antibody-Drug Conjugates (ADC) market is experiencing significant growth, driven by the rising demand for targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. As of 2025, the global ADC market is valued at over USD 8 billion, with projections estimating it will surpass USD 20 billion by 2030, fueled by...
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek